Inmunogenicidad de la vacuna cubana recombitante contra HVB, en niños de 1 a 10 años
Abstract
We evaluated the immunogenecity of the recombinant HBV Cuban vaccine, utilising the 012 months scheme in children between 1 to 10 years of age. Whith the second dose, 98% of after the vaccinated children developed seroprotection (values 210 IU/l) and after the third dose (75 days), 100% had antibody levels > 100 IU/l.
Downloads
Article metrics | |
---|---|
Abstract views | |
Galley vies | |
PDF Views | |
HTML views | |
Other views |